News + Font Resize -

Suven Life Sciences secures 4 product patents for their NCEs in China, Mexico & New Zealand
Our Bureau, Mumbai | Wednesday, April 17, 2013, 14:20 Hrs  [IST]

Suven Life Sciences today announced that it got the grant of two product patents from China (ZL 20088001440 and ZL 200880112735) one product patent each from from Mexico (301421) and New Zealand (591833) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2028.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and schizophrenia.

With these new patents, Suven has a total of 10 granted patents from China, 14 granted product patents from Mexico and 14 granted product patents from New Zealand. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. The Company has 12 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and schizophrenia.

Post Your Comment

 

Enquiry Form